

Diagnos-Techs™

Clinical & Research Laboratory
Quarterly Newsletter

OTHER ARTICLES IN THIS EDITION

- 3 *Timing TAP™ Collections for Shift Workers*
- 4 *The Therapy Corner: Helicobacter pylori*
- 6 *Diagnos-Techs™ Free Webinars*
- 7 *Resources for You*
 - Insurance Billing
 - Technical Services
 - Shipping & Contact Info

Find Diagnos-Techs™ Physicians

John J. White, MD, CM

Often, Diagnos-Techs™ testing may indicate a need for pharmaceutical intervention. For practitioners without prescription-writing privileges, this means finding an allopathic physician or other healthcare practitioner who's experienced in interpreting Diagnos-Techs™ saliva test results and comfortable prescribing medications based on those results.

A comprehensive resource for finding prescription-writing healthcare practitioners who are familiar with Diagnos-Techs™ and the results of our suite of tests is as close as your computer.

Continued on the back page.

The Problem with One-Day Testing for Cycling Women

John J. White, MD, CM



Can a cycling woman's hormones be assessed accurately with just a single day's testing? A newly available one-day, cycling female hormone saliva test certainly sounds like a good -- or at least convenient -- alternative to testing throughout the cycle. However, the reality is that an individual woman's menstrual cycle in no way compares to another's, and a female hormone testing protocol that places mere expedience over accuracy is not of value for any woman.

Diagnos-Techs™ Whole-Cycle Testing Vs. a One-Day Snapshot

For many years, Diagnos-Techs™ has offered female hormone panels specifically designed to deliver an accurate picture of a woman's cycling hormones, without burdening her with unrealistic testing schedules and methods. Our Female Hormone Panel™, for instance, takes a snapshot at 11 discrete points in the menstrual cycle, providing cycle-wide data. Women simply collect saliva at approximately two- to three-day intervals through their cycles, a design that's been well accepted over the years by patients and widely praised by healthcare practitioners for its accuracy and ease-of-collection.

Some labs have introduced a one day menstrual cycle test which involves collecting four vials of saliva on the 21st day of a woman's cycle. The test consists of a circadian cortisol rhythm assessment, plus pooled testosterone, estradiol, and progesterone values. The latter two values are processed with a mathematical formula, purportedly to diagnose luteal phase failure and estrogen dominance.

Continued on page 2.



Diagnos-Techs™ has gone Paperless

In an effort to be more mindful of the environment, we will now be distributing an electronic version of our quarterly newsletter. If you do not have an email address listed on your account, please call **Client Services at 1.800.878.3787** to add your email address.

If you prefer to receive a printed copy of our ChronoBiology Letter, please email us at diagnos@diagnostechs.com.

7 Reasons Why a One-Day Female Hormone Test Doesn't Make the Grade


Without doubt, such a one-day hormone test promotes patient compliance and fits in nicely with a busy schedule. But the relevant issue is whether the data gathered by this test gives an accurate account of a woman's entire cycle. We don't think so, and here's why:

1. Every woman's cycle is unique. Duration, ovulatory timing, luteal phase length, and estradiol and progesterone patterns vary so much that a single-day sample, no matter how "complete," can't compare to the detailed data offered by a multi-sample test. In sports terms, a one-day test is like evaluating a quarterback's performance during a game using four photographs taken in the third quarter.
2. The medical staff at Diagnos-Techs™ has long recognized that hormones follow a circadian rhythm. To reflect this rhythm accurately, specimens are collected throughout the cycle at the same time of day, determined by the patient's convenience.
3. A single-day snippet of a woman's month-long cycle may or may not correctly identify luteal phase failure or estrogen dominance. Though the one-day saliva test in question has been compared to our 11-vial FHP™, it doesn't offer the same detailed picture of hormonal changes over the cycle, necessary for a confident diagnosis of either luteal phase failure or estrogen dominance.
4. One size does not fit all when testing female hormones. For peri- and post-menopausal women, Diagnos-Techs™ offers the PeriM™ (two vials) and PostM™ (one vial) panels. These tests are available in standard versions and expanded panels that test FSH and LH pituitary hormones to provide precisely tailored data without unduly burdensome sample collection. The information gathered by these targeted tests is more pertinent to a woman's particular phase in her cycling life.



Expanded Female Hormone Panel

Figure 1




In this 35-year-old woman with acne and premenstrual problems, a Day 21 analysis (green) would miss significantly elevated late-luteal phase estradiol levels producing estrogen dominance and the dramatic drop in progesterone. In view of the low follicular phase progesterone level, biphasic progesterone supplementation (fixed low-dosage in the follicular phase, plus timed graduated dosing in the luteal phase) seems indicated. This biphasic progesterone deficiency would not be identified using a single Day 21 sample.



Expanded Female Hormone Panel

Figure 2



This 37-year-old woman complained of premenstrual problems and infertility. A single-day assay (green) would miss both estrogen dominance in the last part of the luteal phase and very low progesterone. There is evident need for supplementary progesterone to build up a uterine mucosa sufficient to support a fertilized ovum. Biphasic progesterone supplementation in the follicular phase is warranted in this case, as well.

5. The pattern of progesterone deficiency (follicular and/or early, middle, or late luteal phase), which may produce menopausal or menstrual problems, must be evaluated completely. This pattern then points the way toward an appropriately designed treatment program, which may include biphasic progesterone supplementation (Figure 1).
6. A one-day assay is meaningless for evaluating women with fertility problems. This single test does not provide invaluable sequential FSH and LH measurements, nor does it address multiple issues that may be interacting to cause infertility (Figure 2).
7. Finally, there's the issue of cost. Our comprehensive cycling Female Hormone Panel, which includes 24 individual hormone assays, actually costs \$25 less than the incomplete one-day alternative, which includes only seven assays.

Effective, Lifelong Cycle Management Takes More than a Single-Serving Test

Can a cycling woman's complex hormonal picture be accurately assessed with a one-day test? Years of work with samples collected from women throughout the cycling years tells us that, while convenient, this test lacks the accuracy and cycle-wide insight needed to analyze a woman's hormonal health and well-being. Every woman is one-of-a-kind, and a one-day assessment is not sufficient to provide a complete hormonal picture for her and her alone. In female hormone testing, like clothing, one size does not fit all.

Timing TAP™ Collections for Shift Workers

John J. White, MD, CM



The Temporal Free Cortisol Rhythm Panel (TAP™) highlights cortisol levels across a patient's circadian cycle using four cortisol measurements taken throughout the waking hours. The TAP lies at the heart of the expanded Adrenal Stress Index™ (ASI™), which also measures pooled DHEA/S, 17-hydroxy progesterone, and salivary secretory IgA (SIgA), along with two insulin levels (fasting and random/post-stimulation) and SIgA gliadin levels (gluten sensitivity is a common and often unrecognized stressor).


But what about workers whose schedules are out of sync with the usual waking circadian pattern? We are often questioned about the applicability of circadian cortisol testing for patients whose days are not routine, such as swing shift and nightshift workers. A routine morning-to-midnight collection schedule not only fails to represent accurately their lifestyles and schedules, but would require, at times, waking up to test. This in itself is stressful and most certainly would provoke unnatural cortisol levels.

Analysis of circadian cortisol rhythm patterns underscores the importance of a patient's unperturbed sleep cycle in rejuvenating the adrenals and providing the elevated cortisol levels seen on awakening. Sleep, at whatever time of day, appears central to a regular cortisol rhythm. In light of this, specimen collection times can be adjusted for shift workers to reflect normal "day" centered on their sleep patterns.

To accomplish this, the first cortisol specimen (fasting) should be collected on awakening. The fourth specimen (bedtime) should be collected prior to sleep. The second specimen can be collected around "lunchtime," with the third collected just before "supper." This schedule provides the closest approximation to that of a patient leading a "regular" lifestyle.

Although there is little published experience with data gathered in this way, this collection schedule mimics the standard collection schedule, providing a comparable circadian cortisol rhythm assessment for patients who have adjusted to a nonstandard

sleep/wake cycle. Sleep, the major factor in adrenal rejuvenation, is central to all collection schedules, and data derived in this way definitely has value in assessing cortisol circadian rhythm and any effects of stress on shift workers and others who keep unusual hours.





The Therapy Corner

Helicobacter pylori

Brandy Webb, ND

Helicobacter pylori is a small, curved, rod-shaped bacterium that inhabits the stomach and duodenum. Up to 40% of the U.S. population is infected with or colonized *H. pylori*; most colonization occurs during childhood.¹ Colonization refers to positive *H. pylori* status without symptoms, while infection is reserved for cases where symptoms like dyspepsia are present. Due to a three-to six-fold increased risk of stomach cancer, it is important to identify affected individuals and consider protocols for *H. pylori* eradication.²

Helicobacter pylori's behavior and structure make it particularly effective in colonizing the upper gastrointestinal tract. First, *H. pylori*'s flagella propel it toward the mucosal lining of the stomach or duodenum. Then, its corkscrew-shaped body burrows deep into the gastrointestinal wall beneath the protective layer of mucus. The immune cells dispatched by the body, including killer T-cells, cannot effectively penetrate the mucous layer to reach *H. pylori*. Compounding the problem, the inflammatory effects of immune cell activity (such as the release of free radicals) may contribute to the development of ulcers and dysplasia.³

H. pylori releases enzymes that directly break down the mucous layer, which most likely further contributes to ulcer formation.² Once *H. pylori* has burrowed into the mucosal lining of the stomach or duodenum, it

survives the acidic environment of the stomach by secreting an enzyme called *urease*, which hydrolyzes the surrounding urea into bicarbonate and ammonia, strong bases that neutralize stomach acids.⁴

Helicobacter pylori is spread via fecal-oral transmission (through consumption of contaminated food or water) and by oral-oral transmission (through intimate person-to-person contact). The vast majority of individuals with *H. pylori* never develop symptoms. Of those who do present with symptoms, dyspepsia is the most common. *Dyspepsia* is classified as gnawing or burning pain in the epigastric region, frequently accompanied by bloating, nausea, and abdominal fullness.⁵ Ulcers may or may not be present initially, but there exists a strong association between *H. pylori* and peptic ulcer disease (PUD). *Helicobacter pylori* is implicated in the formation of 90% of duodenal ulcers and 80% of gastric ulcers.⁶

Why Eradication Is Important

Helicobacter pylori colonization is a major cause of gastric adenocarcinoma and increases the risk of gastric mucosa-associated lymphoid tissue (MALT) lymphoma.⁷ In 1994, the International Agency for Research on Cancer formally classified *H. pylori* as a carcinogen in humans.⁷ Furthermore, *H. pylori* is a significant factor in the pathophysiology of hypochlorhydria, gastritis, and peptic ulcer disease. For

these reasons, eradicating *H. pylori* through conventional or natural methods may be warranted, regardless of symptom status.

Salivary IgG *H. Pylori* Testing

Measuring *Helicobacter pylori* IgG levels in saliva is a convenient alternative to other forms of *H. pylori* testing, such as serum IgG, urease breath test, stool antigen testing, and biopsy. Saliva IgG *H. pylori* testing has a sensitivity of 93% and specificity of 83% and is considered "a valuable alternative to invasive procedures" due to its simplicity and practicality.^{8,9} Diagnos-Techs™ offers a convenient salivary IgG *H. pylori* test, which is available alone (lab code GP8-S) or as part of our comprehensive GI panels (lab codes GI-1 and GI-2).

Conventional Treatment

The treatment goal in asymptomatic patients is eradication of the *Helicobacter pylori*; additional therapeutic considerations may be appropriate in symptomatic patients. The scope of this article is limited to adults (for guidelines on treating children, please see the *North American Society for Pediatric Gastroenterology and Nutrition Position Statement*).¹⁰ There are a variety of conventional drug combination protocols available, the most effective involving a "triple-therapy" or "quadruple-therapy" employing bismuth, two antibiotics, and, frequently, a proton-pump inhibitor (PPI). Bismuth helps prevent drug resistance, while the PPI helps heal the damaged mucosa (some sources suggest that PPIs may increase drug resistance). Due to the significant risk of drug

resistance, most pharmacologic agents can be tried only once. If a patient tests positive after initial therapy, consider modifying the drug regimen. The antibiotics most frequently used for *H. pylori* include amoxicillin (*Amoxil*®, *Trimox*®), clarithromycin (*Biaxin*®), and metronidazole (*Flagyl*®).⁵ Commonly prescribed triple- and quadruple-therapies typically last 10-14 days, although newer, shorter regimens are now available. One of the newer protocols, which has demonstrated an impressive eradication rate, involves a one-day quadruple-regimen:⁵

Bismuth subcitrate or subsalicylate (*Kaopectate*®, *Pepto-Bismol*®)—240mg PO QID

Amoxicillin (*Amoxil*®, *Trimox*®)—2g PO QID

Metronidazole (*Flagyl*®)—500mg PO QID

Lansoprazole (*Prevacid*®)—60mg once

There is disagreement on whether longer regimens have significantly greater efficacy; some sources recommend longer courses for better eradication while others prefer shorter courses for better compliance, fewer side effects, and lower cost. A typical longer-course triple-therapy consists of the following (generally given for seven, 10, or 14 days):¹¹

Amoxicillin (*Amoxil*®, *Trimox*®)—1g PO BID

Clarithromycin (*Biaxin*®)—500mg PO BID

Lansoprazole (*Prevacid*®)—30mg PO BID

This particular combination is available from some pharmaceutical companies as a kit of “daily administration cards,” each of which contains all of the pills to be taken on that day. Bismuth subcitrate or

subsalsalicylate may be prescribed separately to achieve a quadruple-therapy. Due to the rampant drug resistance of *Helicobacter pylori*, researchers are continuing to investigate alternative drug protocols. Novel drug regimens that have shown promising results include 1) a 14-day course of nitazoxanide (*Alinia*®) and sucralfate (*Carafate*®);¹² 2) a four-day course of dexlansoprazole (*Dexilant*®, *Kapidex*®), moxifloxacin (*Avelox*®), amoxicillin (*Amoxil*®, *Trimox*®), nitazoxanide (*Alinia*®), and doxycycline (*Adoxa*®, *Vibramycin*®);¹³ and 3) a seven-day course of levofloxacin (*Levaquin*®), omeprazole (*Prilosec*®), nitazoxanide (*Alinia*®), and doxycycline (*Adoxa*®, *Vibramycin*®).¹⁴

It is important to rule out known drug allergies to individual medications before placing any patient on these drug regimens. Also, such protocols may not be suitable for pregnant women, due to the potential for fetotoxicity (there are concerns about using some of these drugs while breastfeeding, as well). Common side effects include nausea, vomiting, diarrhea, dark tongue, and dark stools. For this reason, consider giving adjunctive natural therapies to mitigate specific side effects. A potent probiotic can help minimize bowel disruption, and it can also prevent the fungal overgrowth that can result from antibiotic use. Consider dosing with 50-100 billion CFUs daily, starting on the first day of drug therapy and continuing for a minimum of three weeks after completing the drug course. Ginger, peppermint, and various homeopathic remedies have been demonstrated to relieve nausea and vomiting, while apple pectin can be helpful for diarrhea.

Natural Treatments

There are numerous studies demonstrating the efficacy of natural substances in eradicating *Helicobacter pylori* *in vitro*, but more human trials are needed to fully elucidate which natural agents are effective *in vivo*. The following recommendations may be prescribed alone or in combination with conventional treatment. In either case, repeat testing is recommended to confirm eradication, since many therapies are effective at suppressing infection in the short term but may not completely eradicate *H. pylori*. Natural treatment considerations may include:

Vaccinium macrocarpon (cranberry)—250ml (16oz) juice QD or BID

Allium sativum (garlic)—4mg in divided doses QD

Berberine—300mg TID

Grapefruit seed extract—500mg BID

Vitamin C—5g per day in divided doses

Probiotics—50-100 billion CFU daily per day for two weeks then 30-40 billion CFU per day

There are promising results indicating that *Vaccinium macrocarpon* reduces *H. pylori* adhesion to gastric epithelium and may inhibit enzymes that aid the survival of the bacterium.^{15,16,17,18} Numerous *in vitro* studies demonstrate that *Allium sativum* inhibits *H. pylori* growth, although additional clinical trials are needed to demonstrate this affect *in vivo*.^{19,20,21} Berberine is an alkaloid present in herbs like *Hydrastis canadensis* (goldenseal) and *Mahonia aquifolium* (Oregon grape). This compound possesses inhibitory effects against *H. pylori* *in vitro*.²² Grapefruit seed extract shows antimicrobial activity against a wide

Continued on page 6.

Therapy Corner Continued.

variety of gastrointestinal pathogens, including *H. pylori*.²³ Several studies demonstrate an association between vitamin C supplementation and *H. pylori* prevention and eradication.^{24,25,26} *Bifidobacterium bifidum*, *Lactobacillus casei*, and *Saccharomyces boulardii* have been shown to be effective at inhibiting *Helicobacter pylori*, preventing *H. pylori*-associated ulcer formation and reducing *H. pylori* treatment-related symptoms, respectively.^{27,28,29}

Retesting & Recurrence

Helicobacter pylori IgG titers can remain elevated for an extended period following eradication, so allow many months to pass before repeating salivary IgG testing. If earlier testing is desired, consider a stool antigen test or urease breath test. In these cases, allow at least four weeks after treatment before retesting to assess eradication accurately.

Many natural *Helicobacter pylori* treatment strategies can be used long term to protect the gastrointestinal tract against recolonization. Encourage patients to regularly consume cranberry juice, fresh garlic, and citrus fruits. Broccoli sprouts, green tea, and fermented foods are also associated with reduced incidence of *H. pylori*.³⁰ They appear to work by inhibiting *H. pylori* colonization, decreasing gastric inflammation, and repressing precancerous changes.^{11,30} Dietary recommendations such as these can minimize the risk of *H. pylori* recurrence and related sequelae in treated individuals.

References

- 1 Barzilay EJ, Fagan RP. *Helicobacter pylori*. Centers for Disease Control and Prevention. <http://wwwnc.cdc.gov/travel/yellowbook/2012/chapter-3-infectious-diseases-related-to-travel/helicobacter-pylori.htm>
- 2 *Helicobacter pylori* infection. Merck Manual. http://www.merckmanuals.com/professional/gastrointestinal_disorders/gastritis_and_peptic_ulcer_disease/helicobacter_pylori_infection.html
- 3 The Helicobacter Foundation. *General Information*. http://www.helico.com/h_general.html
- 4 European Bioinformatics Institute. *Bacteria Genomes—Helicobacter pylori*. http://www.ebi.ac.uk/2can/genomes/bacteria/Helicobacter_pylori.html
- 5 Ables AZ, Simon I, Melton ER. *Update on Helicobacter pylori Treatment*. Am Fam Physician. 2007;75(3):351-358.
- 6 *Helicobacter pylori and Peptic Ulcer Disease*. Centers for Disease Control and Prevention.
- 7 National Cancer Institute at the National Institutes of Health. Factsheet: *Helicobacter pylori and Cancer*. <http://www.cancer.gov/cancertopics/factsheet/Risk/h-pylori-cancer>
- 8 Luzzza F, Oderda G, Maletta M, et al. *Salivary immunoglobulin G assay to diagnose Helicobacter pylori infection in children*. J Clin Microbiol. 1997;35(12):3358-60. PMID:9399560
- 9 El-Mekki A, Kumar A, Alkaway B, et al. *Comparison of enzyme immunoassays detecting Helicobacter pylori specific IgG in serum and saliva with endoscopic and biopsy findings in patients with dyspepsia*. Indian J Med Microbiol. 2011;29(2):136-40. PMID:21654107
- 10 Gold BD, Colletti RB, Abbott M, et al. Medical Position Statement: *The North American Society for Pediatric Gastroenterology and Nutrition Helicobacter pylori Infection in Children: Recommendations for Diagnosis and Treatment*. Journal of Pediatric Gastroenterology and Nutrition 2000;31:490-497.
- 11 Crowe SE. *Treatment regimens for Helicobacter pylori*. UpToDate. <http://www.uptodate.com/contents/treatment-regimens-for-helicobacter-pylori>
- 12 Basu PP, Krishnaswamy N, Korapati R, et al. *A New Four-day Regimen with Dexlansoprazole, Moxifloxacin, Amoxicillin, Nitazoxanide, and Doxycycline (DeMAND) in Helicobacter Pylori Therapy: An Open-label Randomized Clinical Trial*. Am J Gastroenterol 2010.
- 13 Basu PP, Rayapudi K, Pacana T, et al. *A Randomized Study Comparing Levofloxacin, Omeprazole, Nitazoxanide, and Doxycycline versus Triple Therapy for the Eradication of Helicobacter pylori*. Amer J Gastroenterol 2011.
- 14 Stuppy W. *Dual Therapy: Nitazoxanide and Sucralfate for the Treatment of Helicobacter pylori*. Amer J Gastroenterol 2010.
- 15 Shmueli H, Burger O, Neeman I, et al. *Susceptibility of Helicobacter pylori isolates to the antiadhesion activity of a high-molecular-weight constituent of cranberry*. Diagn Microbiol Infect Dis 2004;50:231-235.

References continued on back page.

DTI Free Webinars



Diagnos-Techs™ offers fast-paced, patient health-focused webinars on the 2nd and 4th Thursday of each month. Webinars are live and presented at 9:00 a.m. Pacific Time and again at 12:00 p.m. Pacific Time. We encourage questions during and after our webinars. To ensure participants get the most out of our webinars, our medical staff compiles all submitted questions, answers them, and emails the Q&A document to every webinar participant. For information on attending upcoming Diagnos-Techs™ webinars, please contact Client Services at **1-800-878-3787**. To view our previously recorded webinars, please visit the provider section of our website at www.diagnostechs.com.

Upcoming Webinars:

July 26th, 2012 – Hidden Culprits of Common GI Complaints, Part 2

August 9th, 2012 – Hormones and Pregnancy, Part 1

August 23rd, 2012 – Hormones and Pregnancy, Part 2

DIAGNOS-TECHS™ RESOURCES FOR YOU ▼



Billing

Courtesy Service

FROM OUR TEAM OF INSURANCE SPECIALISTS

Our dedicated team of insurance specialists is trained to assist you with insurance-related questions. Avoid payment-processing challenges by letting us help you and your patients navigate the maze of test codes and fees.

As a courtesy, we will submit claims to most insurance companies at our clients' and patients' requests. In addition, we are able to bill insurance carriers for all referring doctors, nurse practitioners, and registered nurses, and we can advise you on which services are billable. Although we are a non-contracted provider with all insurance companies (with the exception of Medicare), most insurance carriers cover our services and are billable. Depending on a patient's benefit plan, insurance companies usually cover our tests at the maximum allowable rates, so there are no out-of-pocket expenses.

Patient Insurance Disclaimer

Diagnos-Techs™, Inc. is a non-contracted provider with all insurance companies. Please verify your out-of-network benefits (including out-of-network deductibles and co-insurances) by contacting your insurance carrier. Diagnos-Techs™, Inc. will bill your insurance at the retail price per line item. If deductibles and/or co-insurances are applied, Diagnos-Techs™, Inc. is obligated by law in the State of Washington to collect.

HIPAA Compliance

The *Health Insurance Portability and Accountability Act of 1996 (HIPAA)* requires us to protect and maintain the privacy of our patients' identifiable health information. The standards are meant to improve the efficiency and effectiveness of the nation's health care system. We are committed to implementing appropriate administrative, technical and physical safeguards to protect the privacy of protected health information. For more information, go to www.diagnostechs.com and click *About Us/Notice of HIPAA Privacy Practices*.



Client Services

Tips for Success

- Have your **account number** or **accession number** ready before you call.
- **Sign up to access results online.** Call Client Services at 1-800-878-3787 for your password.
- We must have your **patient's name** and **date of birth** on all vials and order forms to process samples.
- **Please advise patients** to consult with you if they have questions regarding their medications or test results. We are unable to discuss these topics directly with patients. Medical support is available for provider questions about medications, results, treatment suggestions, and test recommendations at 1-800-878-3787.
- **Cotton Collection Tip:** To ensure adequate saturation of cotton rolls supplied in some of our test kits, instruct patients to wait until their mouths have refilled with the usual amount of saliva before removing and placing rolls in vials.



Contact Us

How to Reach Us

Business Hours

6:30am–5:00pm
Pacific Standard Time (PST)
Monday through Friday,
except major holidays

Corporate Address

19110 66th Avenue S., Building G
Kent, WA 98032 USA

Customer Service

p 800-878-3787 **f** 425-656-2871
p 425-251-0596

Accounting

f 425-264-0612
email billing@diagnostechs.com

Shipping

p 800-878-3787 **f** 253-398-2449

Technical Services

p 800-878-3787 **f** 425-251-0637

Lab Address

Sample Processing
6620 S. 192nd Place, Building J-106
Kent, WA 98032 USA



Please visit us online at
www.diagnostechs.com

www.facebook.com/diagnostechs



Shipping

Free UPS Return Shipping on returned DOMESTIC test kits

STORAGE & MAILING INSTRUCTIONS FOR ALL SPECIMENS

- ☐ Ship samples on the same day as last sample collection (preferred).
- ☐ If not possible, refrigerate samples and ship within 3 days.
No ice bags are required during shipping.
- ☐ Write the patient's name and address on the outside of the box.
- ☐ Include all samples, test form, and, if applicable, a check or a copy of the front and back of insurance card together inside the supplied box. Please be sure to seal the box with clear tape OR the UPS shipping label (US only).

- **US Domestic:** Deliver completed test kit box to any **UPS** location. **www.UPS.com/dropoff** Return shipping to Diagnos-Techs™ is **PRE-PAID**. Kits will arrive within three business days of shipment.
- **International:** Delivery charges apply. Visit our website for access to discounted return shipping via UPS. Deliveries can also be made Monday through Friday via a private courier of your choice. **International deliveries should be addressed to the physical address only, as noted above and to the right. Do not address to the PO Box.**



**INTERNATIONAL
COURIER SHIPPING**
Diagnos-Techs™, Inc.
Sample Processing
6620 S. 192nd Pl., #J-106
Kent, WA 98032
p 425-251-0596



DiagnosTechs™

THE LEADING LAB IN SALIVA TESTING SINCE 1989

19110 66th Avenue South, Building G
Kent, Washington 98032 USA

www.diagnostechs.com

Therapy Corner References *Continued.*

- 16 Yarnell E, Abascal K. *Antiadhesion Herbs. Alternative and Complementary Therapies.* Vol. 14, No. 3, June 2008.
- 17 Lin YT, Kwon YI, Labbe RG, et al. *Inhibition of Helicobacter pylori and associated urease by oregano and cranberry phytochemical synergies.* Appl Environ Microbiol 2005;71:8558–8564.
- 18 Zhang L, Ma J, Pan K, et al. *Efficacy of cranberry juice on Helicobacter pylori infection: A double-blind, randomized placebo-controlled trial.* Helicobacter 2005;10:139–145.
- 19 Sivam GP, Lampe JW, Ulness B, et al. *Helicobacter pylori – in vitro susceptibility to garlic (Allium sativum) extract.* Nutr Cancer 1997;27:118–121.
- 20 Ernst E. *Is garlic an effective treatment for Helicobacter pylori infection?* Arch Intern Med 1999;159:2484–2485.
- 21 Aydin A, Ersoz G, Tekesin O, et al. *Garlic oil and Helicobacter pylori infection.* Am J Gastroenterol 2000;95:563–564.
- 22 Mahady GB, Pendland SL, Stoia A, et al. *In vitro susceptibility of Helicobacter pylori to isoquinoline alkaloids from Sanguinaria Canadensis and Hudrastis Canadensis.* Phytotherapy Research. Mar 2003.
- 23 Heggers JP, Cottingham J, Gusman J, et al. *The Effectiveness of Processed Grapefruit-Seed Extract as An Antibacterial Agent: II. Mechanism of Action and In Vitro Toxicity.* The Journal of Alternative and Complementary Medicine. 2008;8(3):333–340.
- 24 Jarosz M, Dzieniszewski J, Dabrowska-Ufniaz E, et al. *Effects of high dose vitamin C treatment on Helicobacter pylori infection and total vitamin C concentration in gastric juice.* Eur J Cancer Prev. 1998;7(6):449–54.
- 25 Park JH, Kim SY, Kim DW, et al. *Correlation between Helicobacter pylori infection and vitamin C levels in whole blood, plasma, and gastric juice, and the pH of gastric juice in Korean children.* J Pediatr Gastroenterol Nutr. 2003;37(1):53–62.
- 26 Simon JA, Hudes ES, Perez-Perez GI. *Relation of Serum Ascorbic Acid to Helicobacter pylori Serology in US Adults: the Third National Health and Nutrition Examination Survey.* J Am Coll Nutr. 2003;22(4):283–9.
- 27 Chenoll E, Casinos B, Bataller E, et al. *Novel probiotic Bifidobacterium bifidum CECT 7366 strain active against the pathogenic bacterium Helicobacter pylori.* Appl Environ Microbiol. 2011;77(4):1335–43. PMID: 21169430
- 28 Narayan SS, Jalgaonkar S, Shahani S, et al. *Probiotics: current trends in the treatment of diarrhoea.* Hong Kong Med J. 2010;16(3):213–8. PMID: 20519758
- 29 McFarland LV. *Systematic review and meta-analysis of Saccharomyces boulardii in adult patients.* World J Gastroenterol. 2010;16(18):2202–22. PMID: 20458757
- 30 Lee SY, Shin YW, Hahm KB. *Phytochemicals: mighty but ignored weapons against Helicobacter pylori infection.* J Dig Dis. 2008;9(3):129–39. PMID: 18956590

Log onto **diagnostechs.com** and use the geographical listing of providers to find a physician in your area. In just a few clicks, you'll get access to all nearby physicians who are familiar with Diagnos-Techs™ and understand the value of noninvasive and accurate saliva testing.



DiagnosTechs™

THE LEADING LAB IN SALIVA TESTING SINCE 1989

Issue #12 Chronobiology Letter is published quarterly by Diagnos-Techs™ Laboratory, Inc. in Kent, WA, USA as an educational resource for our health care clients. The content in this newsletter is for informational purposes only and is not to be construed as medical advice.

Diagnos-Techs™, Inc.

19110 66th Avenue S.
Building G
Kent, WA 98032 USA

Printed on recycled paper.